We are an oncology company focused on the clinical development of novel therapies for cancer. Our lead programs include a potential best-in-class HDAC inhibitor, Pracinostat, a novel mitochondrial inhibitor, ME-344, and a PI3-kinase delta inhibitor, PWT143.
[ Read more ]
MEI Pharma Adds David Urso as Senior Vice President of Corporate Development and General Counsel
[ April 8, 2014 ]
MEI Pharma Receives Orphan Status for Pracinostat for Treatment of AML
[ February 28, 2014 ]
Click here for our 2013 Annual Review